AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06057922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201 for Injection
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
Study NCT05184426 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Ultrasound study to assess cardiac anatomy and function
Study NCT05184426 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance
Description: MR to assess cardiac anatomy, function and tissue damage
Study NCT05184426 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: Cathteterization to assess coronary anatomy. Intravascular ultrasound to obtained a detailed assessment of vessels anatomy. Guidewire pressure to assess microcirculation
Study NCT05184426 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endomyocardial biopsy
Description: Optic microscopy, immunofluorescence, transmission electron microscopy
Study NCT05239832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Fusion Protein Vaccine
Description: The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Study NCT06560515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Dinoprostone
Description: induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol
Study NCT06560515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Dinoprostone
Description: induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol
Study NCT06561399 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: TACE, Lenvatinib combination with Sintilimab sequential radiotherapy
Description: TACE, Lenvatinib \[8mg(\<60kg)/12mg(>60kg) orally daily\] combination with Sintilimab (200mg administered intravenous injection on Day 1 of each 21-day cycle) for 2 months. Sequential radiotherapy method and dosage are comprehensively evaluated by radiologists, hepatobiliary surgeons, and oncologists, and discussed by a multidisciplinary team
Study NCT05707507 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Place of treatment
Description: Patients with an infectious diseases have to be treated with a specify antimicrobial therapy. The differences between the arms is about the possibility to continue with the treatment in or out of the hospital.
Study NCT05707507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Place of treatment
Description: Patients with an infectious diseases have to be treated with a specify antimicrobial therapy. The differences between the arms is about the possibility to continue with the treatment in or out of the hospital.
Study NCT04943224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: \< 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,
Study NCT04999852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe and Sound Protocol
Description: SSP is a non-invasive acoustic vagus nerve stimulator consisting of 5 hours of filtered and processed music designed to promote efficient regulation of autonomic state, and available through an app. The SSP is delivered via a mobile app and may fall under the heading of medical devices under the category of software functions/mobile medical applications.
Study NCT04999852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
Study NCT04999852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
Study NCT05557825 — intervention group
Intervention type: RADIATION
Intervention: Photobiomodulation Therapy
Description: Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
Study NCT05167981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RETAINWORKS
Description: The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
Study NCT05883943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook® Venous Valve System
Description: The Cook® Venous Valve is a permanent prosthetic, bicuspid, one-way flow valve designed to be percutaneously implanted into the peripheral deep venous system. The Cook® Venous Valve Delivery System is used to percutaneously deliver the Cook® Venous Valve into the deep venous system.
Study NCT06459271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Managing Cancer And Living Meaningfully (CALM)
Description: Our team has developed a brief, manualized, individual and couple-based psychotherapeutic intervention for patients living with advanced cancer and their primary caregivers called Managing Cancer and Living Meaningfully (CALM). CALM is a brief supportive-expressive therapy consisting of 3-6 sessions of 30-60 minutes delivered over the course of 3-6 months. This tailored therapy is focused on the most common challenges and concerns facing individuals living with advanced cancer. These four broad content domains are: 1) symptom management and communication with healthcare providers; 2) changes in self and in relationships with close others; 3) sense of meaning and purpose in life; and 4) hopes and fears about the future and mortality. The aim is to offer patients and caregivers reflective space and a supportive environment to reflect on and process the various practical and profound aspects of their life while facing advanced illness.
Study NCT06025188 — intervention group
Intervention type: OTHER
Intervention: training set
Description: LASSO regression analysis, Logistic regression analysis, Nomogram
Study NCT06250491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep active rTMS with Hesed coil
Description: This brain neurostimulation method targets the motor cortex bilaterally
Study NCT06250491 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Deep active rTMS with Hesed coil
Description: This brain neurostimulation method targets the motor cortex bilaterally
Study NCT06250491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS with Hesed coil
Description: This brain sham neurostimulation method targets the motor cortex bilaterally
Study NCT06250491 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS with Hesed coil
Description: This brain sham neurostimulation method targets the motor cortex bilaterally
Study NCT05439148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection
Description: Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
Study NCT04684901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AlloWrap® Amniotic Membrane
Description: AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair.
Study NCT05048004 — intervention group
Intervention type: PROCEDURE
Intervention: QMODE intervention
Description: Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For standard ablation, a Thermocool Smarttouch SF (Biosense Webster) catheter will be used (50 W, target ablation index of 550).
Study NCT05048004 — intervention group
Intervention type: PROCEDURE
Intervention: QMODE+ intervention
Description: Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For comparison, catheter ablation performed using very high power with a maximum of up tp 90 W (QMODE +) will be used.
Study NCT05730166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Conditioning stimulus
Description: Mechanical stimulus on the upper trapezius of the non-dominant side.
Study NCT05730166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Conditioning stimulus
Description: Mechanical stimulus on the upper trapezius of the non-dominant side.
Study NCT06105034 — intervention group
Intervention type: PROCEDURE
Intervention: interventional techniques, the severity of placental invasion, and various placental positions and suture techniques
Description: Clinically, severe complications of PA include severe obstetric hemorrhage leading to disseminated intravascular coagulopathy (DIC), iatrogenic injury to the ureters, bladder, bowel, respiratory distress syndrome (RDS), acute transfusion reactions, electrolyte imbalance, and renal failure. In women with PA, the expected blood loss at delivery is 3000- 5000 mL, About 90% of patients require a blood transfusion with 40% requiring more than ten units of packed cell transfusion
Study NCT04811183 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pharmaceutical consultation
Description: Selection of patients for a pharmaceutical consultation with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week after consultation. Elements on knowledge and adherence of treatment will be collected.
Study NCT05033847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO cell)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Study NCT05033847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine (Vero cells)
Description: Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
Study NCT05439109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topographical landmark technique of endotracheal tube placement
Description: An endotracheal tube will be placed inside the trachea after measuring the individual's estimated tracheal dimensions.
Study NCT05439109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation guide mark technique of endotracheal tube placement
Description: An endotracheal tube will be placed in this group by using the intubation guide mark.
Study NCT06558656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTQ5082 capsule
Description: Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle.
Study NCT05104125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40 25mg
Description: 25mg of ASC40 orally once daily for 12 weeks.
Study NCT06372353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Exercise
Description: Baduanjin exercise training program was applied to the subjects in the exercise group, 3 days a week, 5 minutes each with warm-up and cool-down exercises, for a total of 24 sessions, 60 minutes each, under supervision, online, via the ZOOM application, for 8 weeks. In addition, the patients did the exercises unsupervised at home once a week. The patients' first sessions were held in the hospital
Study NCT05013372 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD147- CAR T cells
Description: CAR T cells targeting CD147
Study NCT05104125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40 50mg
Description: 50mg of ASC40 orally once daily for 12 weeks.
Study NCT05104125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40 75mg
Description: 75mg of ASC40 orally once daily for 12 weeks.
Study NCT05104125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily for 12 weeks.
Study NCT05291702 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PCNL
Description: Percutaneous nephrolithotomy ( Extraction of the renal stones using the nephroscope/ Ureteroscope )
Study NCT06263972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Stimulation Prefrontal Cortex
Description: The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to prefrontal cortex for 3 weeks.
Study NCT06263972 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shame cortex stimulation
Description: The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with shame low current electrical stimulation to cortex for 3 weeks.
Study NCT06263972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Stimulation to Motor Cortex
Description: The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to Motor cortex for 3 weeks.
Study NCT06263972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: erobic physical activity
Description: Aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment),
Study NCT06263972 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: erobic physical activity
Description: Aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment),
Study NCT04571658 — intervention group
Intervention type: OTHER
Intervention: Communication
Description: The NEPTUNE Match study includes an interdisciplinary Communication Team that will translate findings from the Molecular Nephrology Board (MNB) to inform patients of the matching assessment with ongoing clinical trials. This team has considerable experience with conveying complex biomedical research information to patients and families and includes experts in precision nephrology, nephrology patient \[adult and pediatric\] communication, and health education.
Study NCT05757908 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Long-Acting Beta Agonist
Description: The Investigator will prescribe standard of care LABA to eligible study participants. Participants will self-administer LABA once or twice daily at the maximum feasible standard of care dosage, per the time points specified in the study Schedule of Assessments. LABA should be taken within 1 to 3 hours prior to morning and evening at-home mobile Spirometry testing.
Study NCT06388122 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05218486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
Study NCT04452175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL E-CIGARETTE
Description: JUUL E-CIGARETTE USAGE FOR 24 WEEKS
Study NCT04452175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: JUUL E-CIGARETTE
Description: JUUL E-CIGARETTE USAGE FOR 24 WEEKS
Study NCT06340659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HbAEx
Description: Participants will have a 1-week (3 session) on-boarding period where study interventionists will deliver all necessary equipment (bike, pulse oximeters, etc.) to the participants' home, review the AEx program and prescription, and supervise the first 3 sessions to ensure participant understanding and fidelity of the AEx program. Thereafter, the remaining 33 sessions will be conducted by the participant without the direct supervision (asynchronous telerehabilitation) of the study interventionists. Subjects will cycle on recumbent stationary cycles at moderate-vigorous intensity individualized as 50-70% of heart rate reserve (HRR) and/or 11-14 on Borg Category Ratio-15 Rating of Perceived Exertion (RPE) Scale, for 30-50 minutes per session. Following the completion of each session, during the check-in meeting with the participant, the study interventionist will gather information from the participant (including HR and RPE) for dose quantification.
Study NCT06340659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HbExergame
Description: Participants will cycle as described in the HbAEx protocol while engaging in cognitive training for the duration of cycling. Cognitive training will include 20 levels of difficulty with 8-10 task scenarios in the context of three virtual worlds (environments. In each of the environments, the participant must follow directions and navigate to a destination where the scenario (cognitive task) will be performed. The game will inform the participant of the assigned task and, automatically, determine and inform the participant of the fastest route from the starting point to the scenario destination where the task will be performed. The participant will be required to remember the assigned task, follow the directions and navigate to the destination, and then remember what action is required to complete the task. A scenario-specific cognitive task will be triggered once the destination has been reached. The cycling and cognitive tasks will be completed throughout the sessions.
Study NCT05293886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical Pelvic Floor Muscle Training
Description: In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
Study NCT05293886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Pelvic Floor Muscle Training
Description: Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
Study NCT04959513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LPRF bone block
Description: Guided bone regeneration using an L-PRF bone block (composite graft composed of a xenograft, a membrane from the patient's blood and a collagenous membrane) after a short healing period of 6 to 8 weeks after tooth extraction
Study NCT06530329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical massage
Description: Classical massage was started by general stroking 3 times. Then, it was continued by kneading 3 times. After the kneading movement, fibrocytic nodules on the muscle were searched and friction was applied to the found nodules one by one. The massage of the muscle was completed by applying stroking 3 times. The application was carried out 3 times a week for 2 weeks to evaluate the short-term effect.
Study NCT06530329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Ischemic compression was applied to the trigger points in the upper trapezius muscle using an average pressure of 1 kg at a right angle, and after compression, passive stretching was applied to the upper trapezius muscle 3 times in 20-second periods. The application was performed 3 times a week for 2 weeks to evaluate the short-term effect.
Study NCT05830747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pre-operative drug administration before third molar surgery
Study NCT05424393 — intervention group
Intervention type: DRUG
Intervention: YISAIPU® ( An etanercept biosimilar)
Description: YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
Study NCT05424393 — intervention group
Intervention type: DRUG
Intervention: csDMARDs
Description: csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
Study NCT05092607 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous and Capillary blood sampling
Description: Venous sample at the bend of the elbow (7mL) taken immediately after the nasopharyngeal sample.~Capillary blood sampling, for patients included in participating centers
Study NCT06390670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum Bovinum supplementation
Description: In the experimental procedure each athlete was supplemented with a chronic dose of 25 g/day of COL. Supplement was particularly prepared for the study from a first post-delivery milking and had a high content of IgG (60%; certified Colostrum Bovinum; Agrapak, Poland). The COL was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the COL supplement in 250 mL of plain water.